Showing 481 - 500 results of 7,397 for search 'significant ((((((shape decrease) OR (step decrease))) OR (we decrease))) OR (small decrease))', query time: 0.48s Refine Results
  1. 481
  2. 482
  3. 483
  4. 484
  5. 485

    Long-term divergence of nitrogen and phosphorus dynamics in small lakes across China by Shaojuan Du (22465949)

    Published 2025
    “…We showed that 33.7% of those lakes showed significant decline trend, with national TN/TP ratio of 18.7±4.2 and average decline trend of 0.99/decade (p < 0.05). …”
  6. 486

    The RehaGait® system. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  7. 487

    Flow chart of included patients and dropouts. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  8. 488

    Dataset of the analyzed data. by Johanna Rydja (12300797)

    Published 2025
    “…Step height was normalized postoperatively; all other variables remained significantly worse than the HI. …”
  9. 489

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  10. 490
  11. 491
  12. 492
  13. 493

    Image 2_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

    Published 2024
    “…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
  14. 494

    Image 5_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

    Published 2024
    “…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
  15. 495

    Image 3_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

    Published 2024
    “…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
  16. 496

    Image 1_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

    Published 2024
    “…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
  17. 497

    Image 4_G. vaginalis increases HSV-2 infection by decreasing vaginal barrier integrity and increasing inflammation in vivo.tif by Nuzhat Rahman (16660416)

    Published 2024
    “…</p>Results<p>G. vaginalis inoculated mice infected with HSV-2 had significantly decreased survival rates, increased pathology, and higher viral titers than PBS and L. crispatus inoculated mice. …”
  18. 498

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  19. 499

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  20. 500

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”